ASX/Media RELEASE **November 21, 2008**

Results of Annual Meeting Held November 19, 2008

Watertown, MA (November 21, 2008) – pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PV3), a drug delivery company, held yesterday an Annual Meeting at 11.00am EST at the Novotel Wentworth Hotel, 61-101 Phillip Street, Sydney.

All resolutions were passed by shareholders as follows:

1. Election of Directors.

Director Nominee	FOR	WITHHELD
David J. Mazzo	9,299,701	386,630
Paul Ashton	9,338,537	347,787
Paul A Hopper	9,301,136	385,188
Michael Rogers	9,296,886	389,438
Peter G. Savas	9,301,236	385,088

2. Approval of the grant of options to Managing Director Paul Ashton.

FOR	4,962,270
AGAINST	1,022,612
ABSTAIN	759,265
NON-VOTES	2,943,610

3. Approval of the grants of options to each of four Non-Executive Directors.

	FOR	AGAINST	ABSTAIN	NON VOTES
Paul A. Hopper	4,904,374	1,071,755	759,115	2,952,513
Peter G. Savas	4,904,299	1,071,505	759,440	2,952,513
David J. Mazzo	4,915,107	1,060,772	759,365	2,952,513
Michael Rogers	4,912,457	1,063,672	759,115	2,952,513

4. Approval of the maximum aggregate annual cash compensation for directors.

FOR	7,481,586
AGAINST	1,316,728
ABSTAIN	877,630
NON-VOTES	11,813

5. Ratification of the appointment of Deloitte & Touche LLP.

FOR	8,453,067
AGAINST	432,198
ABSTAIN	799,379
NON-VOTES	3,113

Released by:

pSivida Corp.
Brian Leedman
Vice President, Investor Relations
pSivida Corp.
Tel: +61 8 9227 8327
brianl@psivida.com

US Public Relations
Beverly Jedynak
President
Martin E. Janis & Company, Inc
Tel: +1 (312) 943 1100 ext. 12
bjedynak@janispr.com

About pSivida Corp.

pSivida is a drug delivery company committed to the biomedical sector, with a primary focus on ophthalmology and oncology. pSivida has two products approved by the Food and Drug Administration (FDA): Retisert® for the treatment of uveitis and Vitrasert® for the treatment of AIDS-related cytomegalovirus (CMV) retinitis. pSivida has licensed both of these products and the technologies underlying them to Bausch & Lomb Incorporated. pSivida has one product in fully recruited Phase III clinical trials: Iluvien™, which delivers fluocinolone acetonide (FA) for the treatment of diabetic macular edema (DME), formerly known as Medidur FA for DME. pSivida has licensed certain drug delivery technology to Alimera Sciences, Inc. for the development of Iluvien and certain other ophthalmic products. pSivida has a worldwide collaborative research and license agreement with Pfizer Inc. under which Pfizer may develop additional ophthalmic products.

pSivida owns the rights to develop and commercialize a modified form of silicon known as BioSilicon™, which has potential therapeutic applications. The most advanced BioSilicon product candidate, BrachySil™, delivers a therapeutic P32, a radioactive form of phosphorus used to treat cancer, directly to solid tumors. pSivida recently completed an initial safety and efficacy clinical trial of BrachySil for the treatment of pancreatic cancer and has commenced a dose-ranging clinical trial.

pSivida's intellectual property portfolio consists of 64 patent families, 122 granted patents, including patents accepted for issuance, and 282 patent applications. pSivida conducts its operations from Boston in the United States and Malvern in the United Kingdom.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking and involve a number of risks and uncertainties. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. The following are some of the factors that could cause actual results to differ materially from the forward-looking statements: insufficient funding as a result of termination by our current partners of their licensing and collaboration agreements or their failure to make payments under those agreements or failure of Iluvien to receive FDA approval on schedule, or at all, or failure of Iluvien to generate profit on its commercial sales or insufficient levels of Retisert royalties; inability to raise capital; continued losses and lack of profitability; inability to pay any registration penalties; inability to develop or obtain regulatory approval for new products; inability to protect intellectual property or infringement of others' intellectual property; inability to obtain partners to develop and market products; competition; risks and costs of international business operations; manufacturing problems; insufficient third-party reimbursement for products; failure to retain key personnel; product liability; failure to comply with laws; failure to achieve and maintain effective internal control over financial reporting; impairment of intangibles; volatility of stock price; possible dilution through exercise of outstanding warrants and stock options or future stock issuances; possible influence by Pfizer; and other factors that may be described in our filings with the Securities and Exchange Commission. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. We do not undertake to publicly update or revise our forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied in such statements will not be realized.